Cell-free medicine
Dexonova is a research-stage biotech company developing SHED-EV, exosomes released by stem cells from the pulp of baby teeth, as medicines. We are advancing programs in ophthalmology, immuno-oncology and systemic disease in Japan and the United States.
Dexonova K.K. was formerly named DEXON Pharmaceuticals Co., Ltd.
50–150 nm
The diameter of an exosome: roughly one hundredth the size of a cell, carrying proteins and miRNA inside.
Technology
SHED (stem cells from human exfoliated deciduous teeth) are stem cells obtained from the pulp of baby teeth that fall out naturally. We purify the exosomes from the culture medium of these cells and use the exosomes alone.
LEVER 1
SHED-EV captures destabilized proteins, supports their refolding and promotes the clearance of aggregated peptides. The aim is to stop the chain in which one aggregate seeds the next.
Areas: eye disease, systemic disease, neurodegeneration
LEVER 2
SHED-EV suppresses the activation of cancer-associated fibroblasts (CAFs) and shifts tumor-supporting M2 macrophages toward tumor-attacking M1. It does not kill cancer cells directly. It prepares the ground for the host's own immunity to work.
Area: immuno-oncology
SHED derive from the neural crest and are rich in neurotrophic factors, which suits research on retinal and neural tissue.
Because the product is cell-free, it avoids the tumorigenicity and rejection concerns of cell transplantation. It is also suited to standardization and storage.
We do not use the culture medium as it is. Exosomes are purified and tested for quality at our own cell processing facility.
Pipeline
Ophthalmology leads, because the eye allows local delivery and has established endpoints. Immuno-oncology and systemic disease follow.
Eye drop. Ocular surface inflammation and tear instability
Nonclinical
CAF suppression and M2-to-M1 repolarization
Nonclinical (patented in Japan)
Aggregation of lens crystallins
Discovery
Amyloid-β in drusen
Discovery
Mutant rhodopsin and ER stress
Discovery
Microclots formed by amyloid-type fibrin
Discovery
Amyloid-β, tau and α-synuclein
Discovery
All programs are at the research and development stage. None has been approved as a medicine.
Research
Results of cell and animal studies described in our patent specification (JP 2026-7350 A).
In human fibroblasts stimulated with TGF-β, expression of the CAF marker αSMA fell as the amount of SHED-EV increased.
In human M2 macrophages, the M1 marker TNF-α rose and the M2 marker IL-10 fell.
In mice implanted with melanoma, the tumor signal 21 days after dosing was significantly lower than in the control group (P<0.05, 10 mice per group).
MICE WITHOUT IMMUNITY
No difference from control
In mice lacking T, B and NK cells, no difference was seen in the primary tumor or in metastases.
MICE WITH IMMUNITY
Tumor growth suppressed
The effect appears through the host's immune system. We are studying combination with immune checkpoint inhibitors.
These are results in animals and cells. Efficacy and safety in humans have not been established.
Intellectual property
We pursue protection across composition, process and use.
10
granted patents
JP Patent No. 7946854 (application 2024-107076)
A PCT application has been filed, with national phase entry planned in the US, Europe, China and Korea.
JP Patent No. 7220938 (application 2022-155607)
JP Patent No. 6894652 (application 2020-152115)
JP Patent No. 7007754 (application 2020-191759)
JP Patent No. 6974892 (application 2021-088875)
JP Patent No. 6830286 (application 2020-110422)
JP Patent No. 6684956 (application 2019-220646)
JP Patent No. 7007770 (application 2021-102516)
JP Patent No. 7492757 (application 2022-044972)
JP Patent No. 7720630 (application 2022-167247)
An application for a rejuvenation agent and rejuvenation method (JP 2025-32034 A) is pending. A foundational filing on proteostasis is in preparation.
Team
Founder & CEO, Dexonova K.K.
Chairman & CSO, Dexonova, Inc.
Physician. Vice Director of Edogawa Hospital. Board-certified in urology, transplantation, regenerative medicine and dialysis. Researched cancer gene therapy at the Cleveland Clinic from 1996 to 1999.
Co-Founder & Scientific Advisor
Professor, Tokyo Medical University; formerly at the National Cancer Center Research Institute. A leading researcher in extracellular vesicles and a seven-time Highly Cited Researcher.
President, Dexonova, Inc.
Leads the US company, with responsibility for development strategy toward an FDA IND and for commercialization. Formerly of Cytori Therapeutics.
News
Company